BFM
NAMS icon

Boothbay Fund Management’s NewAmsterdam Pharma NAMS Stock Holding History

Boothbay Fund Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.11M Buy
+121,200
New +$3.99M 0.05% 413
2025
Q1 		– Sell
-57,600
Closed -$1.48M – 1651
2024
Q4 		$1.48M Buy
+57,600
New +$1.22M 0.04% 526

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Boothbay Fund Management's NAMS Position: Q2 2026 in Review

Boothbay Fund Management increased its NewAmsterdam Pharma (NAMS) stake by 31% in Q2 2026, buying an estimated $277K and bringing the position to 35,756 shares worth $1.21M. The position accounts for 0.02% of the portfolio, ranked #986.

Boothbay Fund Management first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.64M in Q1 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Boothbay Fund Management held 35,756 shares of NewAmsterdam Pharma worth $1.21M as of Q2 2026.
  • Boothbay Fund Management bought 8,420 NewAmsterdam Pharma shares in Q2 2026, an estimated $277K.
  • NewAmsterdam Pharma made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #986 holding.
  • Boothbay Fund Management first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
  • Boothbay Fund Management's NewAmsterdam Pharma position peaked at $2.64M in Q1 2025.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.